Found 5 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 31923: A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors

99 years and younger

All genders

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor tyrosine kinase inhibitor. The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as …

Learn More

Insightec - BT015

99 years and younger

All genders

The purpose of this prospective, self-controlled study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis.

Learn More

UPCC 08520: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

99 years and younger

All genders

This is an umbrella research study is designed to learn more about the safety and effectiveness of AMG 510 in combination with different investigational agents. Eligible subjects include adults with KRAS p.G12C Mutation.

Learn More

UPCC 08522 A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

99 years and younger

All genders

Please refer to Protocol Section 2.1 (Objectives. Please refer to Protocol Section 2.2.1 (Primary Endpoints). Please refer to Protocol Section 2.2.2 (Secondary Endpoints).

Learn More

A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia

99 years and younger

All genders

To demonstrate that the addition of ianalumab to standard first-line corticosteroids prolongs Time to Treatment Failure compared to Corticosteroids alone in participants with primary ITP. ITP means immune thrombocytopenia. Time from randomization to treatment failure which is defined as Platelet count below 30G/L after 8 weeks from randomization. Need for …

Learn More